SCHEMBL5100892

SCHEMBL5100892

CSC1=N/C(=C\c2c[nH]c3ncccc23)C(=O)N1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.52
KMT2A Q03164 1/20 0.50
MAPT P10636 2/20 0.45
HPGD P15428 1/20 0.45
HASPIN Q8TF76 4/20 0.45
CCNT1 O60563 2/20 0.45
CDK9 P50750 2/20 0.45
GAA P10253 1/20 0.43
CSNK2A2 P19784 2/20 0.42
CSNK2B P67870 2/20 0.42
CSNK2A1 P68400 2/20 0.42
CHEK2 O96017 1/20 0.42
CDK1 P06493 1/20 0.42
SRC P12931 1/20 0.42
DYRK3 O43781 1/20 0.41
PIM1 P11309 1/20 0.41
DYRK1A Q13627 1/20 0.41
CSNK2A3 Q8NEV1 1/20 0.41
DYRK2 Q92630 1/20 0.41
DYRK1B Q9Y463 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5100901 1.00 CHEK1 (0.52) CHEK1KMT2AMAPTHPGDHASPIN
SCHEMBL1713712 0.84 CHEK1 (0.55) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1713716 0.84 CHEK1 (0.55) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL4891703 0.83 CHEK1 (0.50) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL4891698 0.83 CHEK1 (0.50) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1713971 0.81 CHEK1 (0.55) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1713968 0.81 CHEK1 (0.55) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1714528 0.81 CHEK1 (0.52) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL13676714 0.81 CHEK1 (0.55) CHEK1KMT2AHASPINCCNT1CDK9
SCHEMBL1714530 0.81 CHEK1 (0.52) CHEK1KMT2AHASPINCCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371862-B2 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2008-05-13 US disclosed
US-20070112020-A1 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112020-A1 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K20, MAP3K6, MAP3K1 CHEK1 251/4885KMT2A 1112/4885MAPT 1665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.